PD55-06 PD-L1 X CTLA-4 IN INVASIVE BLADDER CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive IV (PD55)1 Sep 2021PD55-06 PD-L1 X CTLA-4 IN INVASIVE BLADDER CANCER Fabiana Pereira, Tatiana Mattos, Maria Antonieta Silva, Dino Martini Filho, Roni Fernandes, Luis Gustavo Toledo, Luiz Felipe Leitão, and Wagner Montor Fabiana PereiraFabiana Pereira More articles by this author , Tatiana MattosTatiana Mattos More articles by this author , Maria Antonieta SilvaMaria Antonieta Silva More articles by this author , Dino Martini FilhoDino Martini Filho More articles by this author , Roni FernandesRoni Fernandes More articles by this author , Luis Gustavo ToledoLuis Gustavo Toledo More articles by this author , Luiz Felipe LeitãoLuiz Felipe Leitão More articles by this author , and Wagner MontorWagner Montor More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002089.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Programmed death-ligand 1 (PD-L1) is a transmembrane protein that downregulates the immune responses in the intratumoral microenvironment, through its ligation to PD-1 and CD80 (B7-1). Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a glycoprotein originally described in activated T cells, that can downregulate tumor immune response as well, when ligated to B7-1 and B7-2. Both pathways are immunetherapy targets that have been used as treatment options in Oncology. In patients with invasive urothelial bladder cancer, PD-L1 blockers are currently a treatment option, while CTLA-4 studies are still going on to promote clinical improvement with no major side effects. The aim of this study was to compare PD-L1 and CTLA-4 expressions in invasive bladder cancer. METHODS: Using tissue microarray and immunohistochemistry, PD-L1 (Ventana SP263) and CTLA-4 expressions were evaluated in 57 invasive bladder cancer samples, previously molecularly classified as luminal, basal and other. Positive staining for PD-L1 was considered in cancer cells and immune cells, as determined by Ventana guidelines. As CTLA-4 lacks interpretation guidelines for urothelial carcinoma, we used the same PD-L1 criteria. RESULTS: PD-L1 expression was detected in 21,1% and CTLA-4 in 42,2% of the cases. Fisher test and cui-square test revealed that PD-L1 expression in associated with the basal molecular classification (p=0,036), while CTLA-4 positive staining correlate with the luminal classification (p=0,047). Only one specimen in our collection was positive for both. Therefore, statistics confirmed these expressions are excludent (p=0,008), wich means that positive results for PD-L1 are associated with negative results for CTLA-4 and vice versa. CONCLUSIONS: Our results demonstrate that, while some patients may benefit from PD-L1 based immunotherapy, for others, especially the non-respondents, CTLA-4 targeting may be promising. Therefore, as soon as CTLA-4 blockers are approved for bladder cancer, both markers should be tested. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e999-e999 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fabiana Pereira More articles by this author Tatiana Mattos More articles by this author Maria Antonieta Silva More articles by this author Dino Martini Filho More articles by this author Roni Fernandes More articles by this author Luis Gustavo Toledo More articles by this author Luiz Felipe Leitão More articles by this author Wagner Montor More articles by this author Expand All Advertisement Loading ...